ORLANDO, FL, USA (UroToday.com) - A group from Italy discussed the presence and impact of metabolic syndrome (MS) in castration-resistant prostate cancer (CRPC) treated with abiraterone. They retrospectively evaluated a consecutive series of metastatic CRPC patients treated with abiraterone after docetaxel failure. Metabolic syndrome was correlated during treatment, and follow up and was correlated to see if it was an independent predictor of progression-free survival (PFS) or overall survival (OS).
Of 178 patients identified in the study, metabolic syndrome was present in 70, at baseline, before abiraterone initiation, and 11 developed metabolic syndrome during treatment. Median PFS was lower in patients with MS (5 months vs 9 months in without MS). Patients with MS had a 2-fold increased risk of progression (HR 1.9, 95% CI 1.3-2.7, P < 0.001). Overall survival was 16 months and 22 months in patients with and without MS, respectively. MS was not an independent predictor of overall survival.
The group concluded that MS is present before initiation of abiraterone and can develop from treatment of abiraterone. The presence of MS appears to be a risk factor for progression in patients with CRPC treated with abiraterone. Although there was no independent impact on overall survival, further, larger, prospective studies with longer follow-up are needed to evaluate this definitively.
Presented by Vincenza Conteduca, Orazio Caffo, Lisa Derosa, Antonello Veccia, Elisabetta Petracci, Vincenzo Emanuele Chiuri, Matteo Santoni, Daniele Santini, Lucia Fratino, Francesca Maines, Sara Testoni, and Ugo De Giorgi at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Santa Chiara Hospital, Trento, Italy; Division of Medical Oncology II, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy; Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy; Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy; Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy; National Cancer Center CRO, Aviano, Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy
Reported by Mohammed Haseebuddin, MD, medical writer for UroToday.com